Zimmer Biomet Analysts Recommend 'Hold' Rating

Medical device maker receives mixed reviews from Wall Street research firms

Mar. 31, 2026 at 8:40am

Got story updates? Submit your updates here. ›

Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a global medical device company focused on musculoskeletal healthcare, has been given a consensus 'Hold' rating by 22 research firms currently covering the company. The analysts' average 12-month price target for the stock is $106.20.

Why it matters

Zimmer Biomet's stock performance and analyst sentiment are closely watched by investors as the company navigates the competitive orthopedics and medical device market. A 'Hold' rating suggests analysts see limited upside in the near-term, though the company's diverse product portfolio and global footprint provide a stable foundation.

The details

The analyst ratings break down as follows: 4 'Sell' ratings, 10 'Hold' ratings, 7 'Buy' ratings, and 1 'Strong Buy' rating. Several firms, including Needham & Company, UBS Group, and Weiss Ratings, have issued neutral or negative views on the stock citing factors like pricing pressure and market share challenges.

  • Zimmer Biomet reported Q4 2025 earnings on February 10, 2026.
  • The company's next quarterly report is expected in early May 2026.

The players

Zimmer Biomet Holdings, Inc.

A global medical device company focused on musculoskeletal healthcare, headquartered in Warsaw, Indiana.

Needham & Company

A research firm that has a 'Hold' rating on Zimmer Biomet stock.

UBS Group

A research firm that has an 'Underweight' rating and $89 price target on Zimmer Biomet.

Weiss Ratings

A research firm that recently downgraded Zimmer Biomet from a 'Hold' to a 'Sell' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

Zimmer Biomet is expected to report its next quarterly earnings in early May 2026, which will provide further insight into the company's financial performance and analyst sentiment.

The takeaway

Zimmer Biomet's 'Hold' rating from analysts reflects the mixed outlook for the medical device maker, with concerns around pricing pressure and market share challenges offsetting the stability of its diversified product portfolio and global footprint. Investors will be closely watching the company's upcoming earnings report for signs of improvement or continued headwinds.